106 related articles for article (PubMed ID: 18561174)
21. [Molecular biology of juvenile myelomonocytic leukemia (JMML)].
Manabe A
Rinsho Ketsueki; 2010 Jul; 51(7):526-31. PubMed ID: 20693772
[No Abstract] [Full Text] [Related]
22. Mutations in the let-7 binding site - a mechanism of RAS activation in juvenile myelomonocytic leukemia?
Steinemann D; Tauscher M; Praulich I; Niemeyer CM; Flotho C; Schlegelberger B
Haematologica; 2010 Sep; 95(9):1616. PubMed ID: 20460640
[No Abstract] [Full Text] [Related]
23. [Molecular mechanism and progress in treatment of juvenile myelomonocytic leukemia (JMML)].
Koike K; Matsuda K
Rinsho Ketsueki; 2013 Jun; 54(6):538-44. PubMed ID: 23823092
[No Abstract] [Full Text] [Related]
24. Juvenile myelomonocytic leukemia with t(7;11)(p15;p15) and NUP98-HOXA11 fusion.
Mizoguchi Y; Fujita N; Taki T; Hayashi Y; Hamamoto K
Am J Hematol; 2009 May; 84(5):295-7. PubMed ID: 19338047
[TBL] [Abstract][Full Text] [Related]
25. Recurrently affected genes in juvenile myelomonocytic leukaemia.
Obenauer JC; Kavelaars FG; Sanders MA; de Vries ACH; de Haas V; Beverloo HB; De Moerloose B; Lammens T; Dworzak M; Hoogenboezem RM; Valk PJM; Touw IP; van den Heuvel-Eibrink MM
Br J Haematol; 2018 Jul; 182(1):135-138. PubMed ID: 28485469
[No Abstract] [Full Text] [Related]
26. Germ-line mutation of the NRAS gene may be responsible for the development of juvenile myelomonocytic leukaemia.
De Filippi P; Zecca M; Lisini D; Rosti V; Cagioni C; Carlo-Stella C; Radi O; Veggiotti P; Mastronuzzi A; Acquaviva A; D'Ambrosio A; Locatelli F; Danesino C
Br J Haematol; 2009 Dec; 147(5):706-9. PubMed ID: 19775298
[TBL] [Abstract][Full Text] [Related]
27. The strange case of the lost NRAS mutation in a child with juvenile myelomonocytic leukemia.
De Filippi P; Zecca M; Novara F; Lisini D; Maserati E; Pasquali F; Rosti V; Carlo-Stella C; Zavras N; Cagioni C; Zuffardi O; Pagliara D; Danesino C; Locatelli F
Pediatr Blood Cancer; 2012 Sep; 59(3):580-2. PubMed ID: 22183880
[TBL] [Abstract][Full Text] [Related]
28. Subclonal mutations in SETBP1 confer a poor prognosis in juvenile myelomonocytic leukemia.
Stieglitz E; Troup CB; Gelston LC; Haliburton J; Chow ED; Yu KB; Akutagawa J; Taylor-Weiner AN; Liu YL; Wang YD; Beckman K; Emanuel PD; Braun BS; Abate A; Gerbing RB; Alonzo TA; Loh ML
Blood; 2015 Jan; 125(3):516-24. PubMed ID: 25395418
[TBL] [Abstract][Full Text] [Related]
29. RAS-associated lymphoproliferative disease evolves into severe juvenile myelo-monocytic leukemia.
Lanzarotti N; Bruneau J; Trinquand A; Stolzenberg MC; Neven B; Fregeac J; Levy E; Jeremiah N; Suarez F; Mahlaoui N; Fischer A; Magerus-Chatinet A; Cavé H; Rieux-Laucat F
Blood; 2014 Mar; 123(12):1960-3. PubMed ID: 24652966
[No Abstract] [Full Text] [Related]
30. Morphologic and Immunophenotypic Differences in Juvenile Myelomonocytic Leukemias With CBL and Other Canonical RAS-pathway Gene Mutations: A Single Institutional Experience.
Mariani RA; Jennings L; Zhang S; Bhat R; Gong S
J Pediatr Hematol Oncol; 2021 Aug; 43(6):e819-e825. PubMed ID: 33769390
[TBL] [Abstract][Full Text] [Related]
31. Paediatric myelodysplastic syndromes and juvenile myelomonocytic leukaemia: molecular classification and treatment options.
Niemeyer CM; Kratz CP
Br J Haematol; 2008 Mar; 140(6):610-24. PubMed ID: 18302710
[TBL] [Abstract][Full Text] [Related]
32. [Juvenile myelomonocytic leukemia: A three-case series].
Ghariani I; Jmili-Braham N; Regaieg H; Achour B; Ben Youssef Y; Sendi H; Bakir L; Kortas M
Arch Pediatr; 2016 Dec; 23(12):1264-1269. PubMed ID: 27789175
[TBL] [Abstract][Full Text] [Related]
33. A rare finding of deletion 5q in a child with juvenile myelomonocytic leukemia.
Meck JM; Otani-Rosa JA; Neuberg RW; Welsh JA; Mowrey PN; Meloni-Ehrig AM
Cancer Genet Cytogenet; 2009 Dec; 195(2):192-4. PubMed ID: 19963125
[No Abstract] [Full Text] [Related]
34. [Myelodysplastic syndrome in children].
Yoshimi-Noellke A
Rinsho Ketsueki; 2009 Oct; 50(10):1560-9. PubMed ID: 19915367
[No Abstract] [Full Text] [Related]
35. Concurrent somatic KRAS mutation and germline 10q22.3-q23.2 deletion in a patient with juvenile myelomonocytic leukemia, developmental delay, and multiple malformations: a case report.
Yao R; Yu T; Xu Y; Li G; Yin L; Zhou Y; Wang J; Yan Z
BMC Med Genomics; 2018 Jul; 11(1):60. PubMed ID: 30012129
[TBL] [Abstract][Full Text] [Related]
36. A Case of Uveitis in a Patient With Juvenile Myelomonocytic Leukemia Successfully Treated With Adalimumab.
Cortellazzo Wiel L; Pastore S; Taddio A; Tommasini A
J Pediatr Hematol Oncol; 2020 Jul; 42(5):e373-e376. PubMed ID: 30807392
[TBL] [Abstract][Full Text] [Related]
37. Gene mutations do not operate in a vacuum: the increasing importance of epigenetics in juvenile myelomonocytic leukemia.
Flotho C
Epigenetics; 2019 Mar; 14(3):236-244. PubMed ID: 30773984
[TBL] [Abstract][Full Text] [Related]
38. JMML and RALD (Ras-associated autoimmune leukoproliferative disorder): common genetic etiology yet clinically distinct entities.
Calvo KR; Price S; Braylan RC; Oliveira JB; Lenardo M; Fleisher TA; Rao VK
Blood; 2015 Apr; 125(18):2753-8. PubMed ID: 25691160
[TBL] [Abstract][Full Text] [Related]
39. Diagnostic considerations in juvenile myelomonocytic leukemia in tropical settings.
Misra A; Chopra A; Kumar R; Bakhshi S
Int J Lab Hematol; 2017 Jun; 39(3):e77-e79. PubMed ID: 28263030
[No Abstract] [Full Text] [Related]
40. Fusion driven JMML: a novel CCDC88C-FLT3 fusion responsive to sorafenib identified by RNA sequencing.
Chao AK; Meyer JA; Lee AG; Hecht A; Tarver T; Van Ziffle J; Koegel AK; Golden C; Braun BS; Sweet-Cordero EA; Smith CC; Dvorak CC; Loh ML; Stieglitz E
Leukemia; 2020 Feb; 34(2):662-666. PubMed ID: 31511612
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
